)
Visual
test
Aldeyra Therapeutics
Aldeyra Therapeutics (ALDX) investor relations material
Aldeyra Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary27 Feb, 2026
Executive summary
Focused on developing therapies for immune-mediated diseases, with late-stage candidates reproxalap (for dry eye disease and allergic conjunctivitis) and ADX-2191 (for primary vitreoretinal lymphoma and retinitis pigmentosa).
No products approved for sale as of December 31, 2025; revenue generation depends on regulatory approvals and successful commercialization.
Entered an exclusive option agreement with AbbVie for reproxalap, with potential for significant milestone and royalty payments.
Financial highlights
Net loss for 2025 was $33.8 million, a decrease from $55.9 million in 2024.
Research and development expenses were $25.7 million in 2025, down from $48.2 million in 2024, primarily due to lower clinical and manufacturing costs.
General and administrative expenses were $9.6 million in 2025, down from $11.9 million in 2024.
Cash and cash equivalents totaled $70.0 million at year-end 2025.
Stockholders’ equity was $44.3 million as of December 31, 2025.
Outlook and guidance
Cash and cash equivalents expected to fund operations for at least twelve months from February 27, 2026.
Additional capital will be needed for continued development and commercialization activities.
Awaiting FDA decision on reproxalap NDA resubmission, with a PDUFA date extended to March 16, 2026.
Reproxalap NDA: Field trial impact on approval?
AbbVie option: Financial impact if not exercised?
Next-gen RASP modulators: Development focus?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Aldeyra Therapeutics
- Reproxalap nears FDA decision, targeting rapid relief in dry eye and allergy with AbbVie partnership.ALDX
Oppenheimer 36th Annual Healthcare Life Sciences Conference25 Feb 2026 - RASP modulator pipeline advances with key milestones and strong financials for 2024–2025.ALDXStatus Update3 Feb 2026
- Reproxalap met its Phase 3 endpoint, enabling NDA resubmission and potential commercial partnership.ALDXStudy Update2 Feb 2026
- Late-stage dry eye trials, AbbVie partnership, and diverse pipeline drive near-term catalysts.ALDXJefferies 2024 Global Healthcare Conference1 Feb 2026
- NDA resubmission for rapid-acting dry eye therapy is imminent, with robust pipeline progress.ALDXH.C. Wainwright 26th Annual Global Investment Conference 202420 Jan 2026
- Lead drug for dry eye nears FDA decision, with AbbVie partnership and broad pipeline expansion.ALDXJefferies London Healthcare Conference 202412 Jan 2026
- Late-stage eye drug developers outlined novel therapies and 2024 launch milestones.ALDXCiti's 2024 Global Healthcare Conference11 Jan 2026
- FDA requires more efficacy data for reproxalap; NDA resubmission targeted for mid-2025.ALDXStatus Update26 Dec 2025
- Reproxalap's rapid-acting dry eye therapy and robust RASP pipeline drive near-term milestones.ALDXLeerink’s Global Healthcare Conference 202526 Dec 2025
Next Aldeyra Therapeutics earnings date
Q1 20261 May, 2026
Aldeyra Therapeutics
Next Aldeyra Therapeutics earnings date
Q1 20261 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage